CAMBRIDGE,MA,Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, has secured $7 million in seed financing.
Thymmune Therapeutics secured $7 million in seed financing led by Pillar VC, with participation from NYBC Ventures and other investors. Its investor base includes industry pioneers Mark Bamforth, Founder of Brammer Bio and Arranta Bio, James Fordyce, John Maraganore, Ph.D., Former Founding CEO at Alnylam, Judy Pagliuca at PagsGroup, and Philip Reilly, M.D., J.D., along with George Church, Ph.D., who is a scientific advisor to the company.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
